DYN

9.24

1.49% -0.14

Dopo l'orario di chiusura: 9.20 -0.04 -0.43%

Dyne Therapeutics Inc (DYN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché DYN Giù? Forum Previsione

Precedente Chiudi:

$9.38

Aprire:

$9.26

Volume 24 ore:

1.31M

Relative Volume:

0.46

Capitalizzazione di mercato:

$1.05B

Reddito:

Utile/perdita netta:

$-294.51M

Rapporto P/E:

-2.5955

EPS:

-3.56

Flusso di cassa netto:

$-244.42M

1 W Prestazione:

-1.70%

1M Prestazione:

-13.08%

6M Prestazione:

-32.65%

1 anno Prestazione:

-78.88%

Intervallo 1D:

$9.12

$9.425

Intervallo di 1 settimana:

$8.95

$9.5993

Portata 52W:

$6.36

$47.45

Dyne Therapeutics Inc Stock (DYN) Company Profile

Nome

Dyne Therapeutics Inc

Settore

Healthcare (1161)

Industria

Biotechnology (651)

Telefono

(781) 786-8230

Indirizzo

1560 TRAPELO ROAD, WALTHAM

Dipendente

192

Cinguettio

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

DYN's Discussions on Twitter

Confronta DYN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
DYN Dyne Therapeutics Inc	9.24	1.33B	0	-294.51M	-244.42M	-3.56
VRTX Vertex Pharmaceuticals Inc	472.27	120.73B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	564.64	61.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	328.00	42.46B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	591.74	35.22B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	296.46	31.99B	3.81B	-644.79M	-669.77M	-6.24

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-24	Iniziato	Bernstein	Mkt Perform
2025-06-11	Ripresa	Raymond James	Outperform
2025-06-02	Ripresa	Oppenheimer	Outperform
2025-05-29	Iniziato	Evercore ISI	Outperform
2025-03-12	Iniziato	BMO Capital Markets	Outperform
2025-03-07	Iniziato	Scotiabank	Sector Outperform
2024-12-13	Iniziato	Robert W. Baird	Outperform
2024-11-26	Iniziato	RBC Capital Mkts	Outperform
2024-10-24	Downgrade	JP Morgan	Overweight → Neutral
2024-05-21	Reiterato	Chardan Capital Markets	Buy
2024-04-30	Iniziato	Morgan Stanley	Overweight
2024-02-20	Iniziato	H.C. Wainwright	Buy
2023-02-27	Aggiornamento	Raymond James	Outperform → Strong Buy
2023-02-15	Iniziato	Oppenheimer	Outperform
2023-01-26	Iniziato	Guggenheim	Buy
2022-07-20	Iniziato	Chardan Capital Markets	Buy
2022-07-12	Iniziato	Raymond James	Outperform
2020-10-12	Iniziato	JP Morgan	Overweight
2020-10-12	Iniziato	Jefferies	Buy
2020-10-12	Iniziato	Piper Sandler	Overweight
2020-10-12	Iniziato	Stifel	Buy

Mostra tutto

Dyne Therapeutics Inc Borsa (DYN) Ultime notizie

Jul 24, 2025

Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional

Jul 24, 2025

Jul 23, 2025

What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional

Jul 23, 2025

What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - WV News

Jul 22, 2025

Jul 21, 2025

Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional

Jul 21, 2025

Jul 18, 2025

Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat

Jul 18, 2025

Jul 16, 2025

Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey

Jul 16, 2025

Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus

Jul 16, 2025

Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha

Jul 16, 2025

Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan

Jul 16, 2025

Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN

Jul 16, 2025

Jul 15, 2025

Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest

Jul 15, 2025

DYN CEO Makes Significant Stock Purchase, Shares Rise | DYN Stoc - GuruFocus

Jul 15, 2025

How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com

Jul 15, 2025

Jul 12, 2025

Evercore ISI Analyst Lowers Dyne Therapeutics Price Target to $41, Maintains Outperform Rating - AInvest

Jul 12, 2025

RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT - Yahoo Finance

Jul 12, 2025

Jul 11, 2025

Dyne Therapeutics (DYN) Sees Price Target Reduced by Evercore IS - GuruFocus

Jul 11, 2025

Jul 10, 2025

Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks

Jul 10, 2025

Jul 08, 2025

RBC Capital Sticks to Their Buy Rating for Dyne Therapeutics (DYN) - The Globe and Mail

Jul 08, 2025

Jul 07, 2025

Dyne Therapeutics shares rise 2.08% after-hours following RBC's price target cut to $25. - AInvest

Jul 07, 2025

Jul 05, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jul 05, 2025

Jul 04, 2025

(DYN) Trading Report - news.stocktradersdaily.com

Jul 04, 2025